Business Context and Reporting Period
The filing is a Form 10-K for MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc. It covers the period from September 11, 2020, inception, through December 31, 2020, and was filed March 31, 2021. MedTech was an early-stage blank-check company formed to pursue an initial business combination, with an intended focus on U.S. healthcare and medical technology businesses. It had not completed a business combination or commenced operating activities as of year-end.
The company completed its initial public offering on December 22, 2020, selling 25,000,000 units at $10.00 per unit. Each unit included one Class A share and one-third of a redeemable warrant.
Key Financial Metrics
| Metric | Period Ended December 31, 2020 |
|---|---|
| Revenue | No operating revenue |
| Net loss | $105,195 |
| General and administrative expenses | $108,493 |
| Interest income | $3,298 |
| Cash used in operating activities | $677,599 |
| Cash and investments in trust account | $250,003,298 |
| Cash outside trust account | $1,334,998 |
| Total assets | $252,011,496 |
| Total liabilities | $8,853,216 |
| Class A shares subject to possible redemption | 23,815,827 shares at $10.00 per share, or $238,158,270 |
| Stockholders’ equity | $5,000,010 |
| Debt | No long-term debt; a $178,080 sponsor promissory note was repaid at the IPO closing |
The company raised $250.0 million in the IPO and $7.4 million from the private placement of 4,933,333 warrants. Total offering and transaction costs were $14.2 million, including $8.75 million of deferred underwriting fees payable only if a business combination is completed. The trust account held approximately $250.0 million, invested primarily in U.S. Treasury securities.
Operating margins are not meaningful because the company had no operating revenue. Basic and diluted loss per Class B share was $0.02; Class A earnings per share were zero after allocating trust-account interest and related taxes.
Material Changes Versus the Prior Comparable Period
No prior comparable annual operating period exists because the company was incorporated on September 11, 2020. The principal activity during the reporting period was formation, the IPO, the private placement, and establishment of the trust account.
- The company moved from formation activities to public-company status following the December 22, 2020 IPO.
- All 25,000,000 public units were issued, including 3,000,000 units from a partial exercise of the underwriters’ over-allotment option.
- Founder shares were reduced by 75,000 shares following the partial over-allotment exercise, leaving 6,250,000 Class B shares outstanding.
- The company began accruing a $10,000 monthly fee to its sponsor for office space, utilities, secretarial, and administrative support.
- Public units began trading in December 2020; the Class A shares and warrants began separate trading on February 8, 2021.
Outlook, Risks, Contingencies, and Unusual Items
Management expected to use the trust-account proceeds to complete an initial business combination. The company had until December 22, 2022 to complete the transaction. If it failed to do so, it would be required to cease operations, redeem the public shares, and liquidate; the warrants would expire worthless.
- The proposed target must generally have a fair market value of at least 80% of the trust-account assets, excluding deferred underwriting discounts and net of taxes payable.
- Public stockholders may redeem shares for their pro rata portion of the trust account, initially approximately $10.00 per share, subject to applicable conditions and a minimum post-redemption net tangible asset requirement of $5,000,001.
- The company had no definitive business combination agreement or third-party financing arrangement as of the filing.
- Additional debt or equity financing may be required if the target is larger than the available trust funds or if significant redemptions occur.
- Management and the sponsor face potential conflicts because they own founder shares and private placement warrants and may have obligations to present opportunities to other entities.
- Trust-account funds could be reduced by creditor claims, bankruptcy proceedings, taxes, or unenforceable waivers. The sponsor’s indemnification commitment may not be sufficient because the filing states that the sponsor’s principal assets are company securities.
- The COVID-19 pandemic could negatively affect the company’s financial position, operations, or ability to identify and complete a target transaction, although the specific impact was not determinable.
- The company accrued a deferred underwriting fee of $8.75 million, payable only upon completion of a business combination.
- Management reported effective disclosure controls as of December 31, 2020. No management assessment or auditor attestation of internal control over financial reporting was included because of the applicable transition period for newly public companies.
Most Important Facts to Verify
- Confirm the filing entity: the supplied filing is for MedTech Acquisition Corporation, not Trisalus Life Sciences, Inc.
- Verify whether a subsequent business combination was completed and identify the resulting operating company, transaction terms, dilution, and redemption activity.
- Verify the status and final disposition of the $250.0 million trust account and the $8.75 million deferred underwriting fee.
- Review subsequent filings for changes in the December 22, 2022 liquidation deadline, extensions, or amendments to redemption rights.
- Assess sponsor, officer, and director conflicts, including founder-share conversion, private placement warrants, related-party fees, and any working-capital loans.
- Evaluate the potential dilution from 13,266,666 public and private placement warrants, founder shares, and any securities issued in a business combination.
- Review creditor-claim and bankruptcy risks that could reduce the public-share redemption amount below $10.00 per share.